In a pooled analysis of two studies (AURA phase II extension cohort and AURA 2), outcomes were examined for patients who had EGFR mutation-positive NSCLC, whose disease had progressed following previous EGFR-TKI therapy, whose tumors harbored EGFRT790M, and who had been treated with osimertinib at 80 mg/day. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.